reports
Vistra Corp: 1 director
A director at Vistra Corp sold 25,000 shares at 171.667USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employmen...
- Wedbush Research
BIIB BIOGEN INC.
OVID OVID THERAPEUTICS
FMCC FEDERAL HOME LOAN MORTGAGE CORPORATION
BEAM BEAM THERAPEUTICS
FNMA FEDERAL NATIONAL MORTGAGE ASSOCIATION
VERA VERA THERAPEUTICS INC
ATXS ASTRIA THERAPEUTICS INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
TLX TELIX PHARMACEUTICALS LIMITED
JBIO JADE BIOSCIENCES INC
- Dylan Shindler
- Laura Chico
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Glob...
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami Beach, FL from June 9 – 11, 2025. The management team will also p...
Titan Pharmaceuticals Announces Filing of Registration Statement for P...
Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd. NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec Sdn. Bhd. (f/k/a KE Sdn. Bhd.) (“TalenTec”), which includes Titan’s preliminary proxy statement (the “Form F-4”) As previously announced on ...
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global ...
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. E.T. A live webcast of the Company presentation will be available through the investor relations section of...
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facili...
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has entered into a new credit facility providing for up to $500 million of term loans with its current partner Oxford Finance LLC (“Oxford”). The new credit facility will replace Vera’s existing $50 million...
- Dylan Shindler
- Laura Chico
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reducti...
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p
Universal Technical Institute Inc: 1 director
A director at Universal Technical Institute Inc sold 500,000 shares at 35.000USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Akero Therapeutics to Present at the Jefferies Global Healthcare Confe...
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m. P.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at . Foll...
QNB Corp. Declares Q2 2025 Dividend
QNB Corp. Declares Q2 2025 Dividend Dividend payable on June 27, 2025 Quakertown, PA, May 20, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of QNB Corp. (OTCQX: QNBC), parent company of QNB Bank, at a regular meeting on May 20, declared a quarterly cash dividend of $0.38 per share. The cash dividend is payable on June 27, 2025, to shareholders of record June 13, 2025. QNB Corp. offers commercial and retail banking services through the twelve banking offices of its subsidiary, QNB Bank. QNB Corp.’s stock is traded in the over-the-counter market under the symbol “QNBC.” For more info...
Akero Therapeutics Reports First Quarter 2025 Financial Results and Pr...
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) Presented two oral presentations and a poster presentation highlighting the latest data and new analyses from 96-week SYMMETRY and HARMONY clinical studies at EASL Congress 2025 SYMMETRY study results published in New England Journal of Medicine Raised $402.5 million in gross proceeds in a follow-on public offering...
- Wedbush Research
SHAK SHAKE SHACK INC. CLASS A
DEI DOUGLAS EMMETT INC
HPP HUDSON PACIFIC PROPERTIES INC.
XENE XENON PHARMACEUTICALS INC
WING WINGSTOP INC.
WEN WENDY'S COMPANY
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TXRH TEXAS ROADHOUSE INC.
TSLA TESLA INC
TRNO TERRENO REALTY CORPORATION
STKS ONE GROUP HOSPITALITY
STAG STAG INDUSTRIAL INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBUX STARBUCKS CORPORATION
PZZA PAPA JOHN'S INTERNATIONAL INC.
PEGA PEGASYSTEMS INC.
OFC CORPORATE OFFICE PROPERTIES TRUST
MCD MCDONALD'S CORPORATION
JACK JACK IN THE BOX INC.
IMAX IMAX CORPORATION
EGP EASTGROUP PROPERTIES INC.
EAT BRINKER INTERNATIONAL INC.
DIN DINE BRANDS GLOBAL INC.
DENN DENNY'S CORPORATION
CTMX CYTOMX THERAPEUTICS INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CAKE CHEESECAKE FACTORY INCORPORATED
BXP BOSTON PROPERTIES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
BJRI BJ'S RESTAURANTS INC.
FRX_CN FENNEC PHARMACEUTICALS
CMG CHIPOTLE MEXICAN GRILL INC.
DRI DARDEN RESTAURANTS INC.
WVE WAVE LIFE SCIENCES
PLYM PLYMOUTH INDUSTRIAL REIT INC.
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
YMAB Y-MABS THERAPEUTICS
TVTX TRAVERE THERAPEUTICS INC
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
TNGX TANGO THERAPEUTICS
VERA INC
BROS VERA THERAPEUTICS INC
STRW DUTCH BROS INC
CAVA STRAWBERRY FIELDS REIT INC.
JBIO CAVA GROUP INC
JADE BIOSCIENCES
INC.
- Dylan Shindler
- Laura Chico
Akero Therapeutics und HistoIndex präsentieren neue Analysen der Phase...
Akero Therapeutics und HistoIndex präsentieren neue Analysen der Phase-IIb-Studie HARMONY in Vorträgen und Postern auf dem EASL-Kongress 2025 Die Analyse der Ergebnisse zu EFX mit KI-basierter digitaler Pathologie unterstreicht den potenziellen Wert bei der Bewertung des histopathologischen Ansprechens Die Daten tragen dazu bei, dass die antifibrotische Wirkung von EFX bei Patienten mit präzirrhotischer MASH immer deutlicher wird SOUTH SAN FRANCISCO, Kalifornien, May 11, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), ein im klinischen Stadium tätiges Unternehmen, das ...
Akero Therapeutics et HistoIndex présentent de nouvelles analyses de l...
Akero Therapeutics et HistoIndex présentent de nouvelles analyses de l’essai de phase IIb HARMONY lors de présentations orales et d’affiches lors du congrès 2025 de l’EASL L’analyse des résultats de l’EFX au moyen de la pathologie numérique basée sur l’IA souligne le potentiel d’évaluation de la réponse histopathologique Ces données s’ajoutent au nombre croissant de preuves de l’activité anti-fibrotique de l’EFX chez les patients atteints de MASH pré-cirrhotique SOUTH SAN FRANCISCO, État de Californie, 11 mai 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ : AKRO), une soc...
Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnis...
Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der Fibrose ohne Verschlechterung der MASH SOUTH SAN FRANCISCO, Kalifornien, May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), ein in der klinischen Phase tätiges Unternehmen, das bahnbrechende Therapien für Patienten mit schwerwiegenden Stoffwechselkrankheiten entwickelt, für die ein hoher medizinischer Bedarf besteht, ha...
Akero Therapeutics présente les résultats de la 96e semaine de l’essai...
Akero Therapeutics présente les résultats de la 96e semaine de l’essai clinique de phase 2b SYMMETRY sur l’éfruxifermine chez des patients atteints de cirrhose compensée causée par une stéatohépatite associée à un dysfonctionnement métabolique (MASH), montrant une amélioration de la fibrose sans aggravation de la MASH lors du congrès 2025 de l’EASL SOUTH SAN FRANCISCO, État de Californie, 10 mai 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ : AKRO), une société en phase clinique développant des traitements révolutionnaires pour les patients atteints de maladies métaboliques gr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.